LBRX LB PHARMACEUTICALS INC

8-K Current Report

Filed: March 10, 2026

Health Care

Pharmaceutical Preparations

LB PHARMACEUTICALS INC (LBRX) 8-K current report filed with SEC EDGAR on March 10, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 5.02: Departure/Election of Directors or Officers
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• Robert A. Lenz appointed to Board Mar 6, 2026; Class I director term expiring 2026 annual meeting; joins Nominating and Corporate Governance Committee
• Lenz compensation: $45,000 total annual retainer ($40K board + $5K committee) plus initial 20,000-share option grant vesting over 3 years

+2 more insights

Item 7.01 · Regulation FD Disclosure

• Dr. Lenz appointed to Board of Directors, effective March 9, 2026
• Board composition change signals potential strategic or scientific advisory shift for LBRX

+1 more insights

Other LB PHARMACEUTICALS INC 8-K Filings

8-K Mar 16, 2026

Get deeper insights on LB PHARMACEUTICALS INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.